Endocrine Abstracts

Since 2011 trimethylamine N-oxide (TMAO) has been established as a cardiovascular risk biomarker in various patient populations. Previous studies have shown the association of TMAO levels with insulin resistance and diabetes. Additionally, a higher risk of cardiovascular events has been observed in patients with type 2 diabetes and higher levels of TMAO. However, the direct link between TMAO levels and kidney function in patients with diabetes is still unclear. Our objective w...